A Phase 1 Study of the Combination of BH3-mimetic, Navitoclax, and Mtorc1/2 Inhibitor, Vistusertib, in Patients with Advanced Solid Tumors.
Cancer Chemotherapy and Pharmacology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined